BLAORALCAPSULE, DELAYED RELEASE
Approved
May 2012
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
4
Data completeness
5/8 — Partial
PERTZYE (pancrelipase) by AbbVie is lipases, proteases, and amylases that catalyze the hydrolysis of fats to monoglyceride, glycerol and free fatty acids, proteins into peptides and amino acids, and starches into dextrins and short chain sugars such as maltose and maltotriose in the duodenum and proximal small intestine, thereby acting like digestive enzymes physiologically secreted by the pancreas. Approved for exocrine pancreatic insufficiency, cystic fibrosis. First approved in 2012.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PERTZYE is an oral delayed-release capsule containing pancrelipase (a combination of lipases, proteases, and amylases) approved for exocrine pancreatic insufficiency in adults. It replaces missing pancreatic digestive enzymes, enabling the breakdown of fats, proteins, and starches in the small intestine. The product mimics the physiological function of naturally secreted pancreatic enzymes.
$0.007BPart D
PeakPERTZYE is in peak commercial lifecycle with modest Part D spending of $7M and 1,578 claims in 2023, indicating a stable but niche market position requiring focused commercial and specialty team management.
Mechanism of Action
lipases, proteases, and amylases that catalyze the hydrolysis of fats to monoglyceride, glycerol and free fatty acids, proteins into peptides and amino acids, and starches into dextrins and short chain sugars such as maltose and maltotriose in the duodenum and proximal small intestine, thereby…
Indications (2)
Worked on PERTZYE at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.